Genetic aberrations involved in relapse of pediatric acute myeloid leukemia: A literature review.
acute
gene expression
leukemia
myeloid
pediatrics
recurrence
Journal
Asia-Pacific journal of clinical oncology
ISSN: 1743-7563
Titre abrégé: Asia Pac J Clin Oncol
Pays: Australia
ID NLM: 101241430
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
29
11
2018
accepted:
27
04
2020
pubmed:
24
6
2020
medline:
27
11
2021
entrez:
24
6
2020
Statut:
ppublish
Résumé
Globally, 15-20% of all children diagnosed with leukemia suffer from acute myeloid leukemia (AML), a rapidly progressive, clinically and biologically heterogeneous disease leading to the impaired differentiation of myeloid blast cells. Although 80% of patients achieve complete remission after induction chemotherapy, many relapse, negatively affecting overall out comes. The mechanisms underlying relapse have not been fully elucidated. This review aims to provide an overview of genetic aberrations involved in relapse of disease. A literature review on molecular mechanisms implicated in pediatric AML relapse spanning from 2003 to 2017 was conducted. PubMed, Medline, and Google Scholar were interrogated using relevant search terms. Of note, we examined a total of final 10 research papers from four large study groups that have utilized whole genome sequencing and molecular targeting of trio or paired samples of initial diagnosis, remission, and relapse. Their findings reveal that the genomic landscape of pediatric AML varies from diagnosis to relapse in different populations. Pediatric AML relapse is a systemic evolutionary illness accompanied by synchronized mutational hits impairing differentiation function. The irregular proliferative function is a consequence of mutations in signal transduction genes such as FLT3, RAS, PTPN11, and c-KIT and genes that code for transcription factors such as CEBPα, WT1, SATB1, GFI1, KLF2, and TBP are associated with relapse of disease. Identification of molecular markers unique to different stages of the disease in distinct populations can provide valuable information about disease prognosis and management.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e135-e141Informations de copyright
© 2020 John Wiley & Sons Australia, Ltd.
Références
Rubnitz JE. Current management of childhood acute myeloid leukemia. Pediatric Drugs. 2017;19:1-10.
Klein K, de Haas V, Kaspers GJL. Clinical challenges in de novo pediatric acute myeloid leukemia. Expert Rev Anticancer Ther. 2018;18:277-293.
Tarlock K, Alonzo TA, Moraleda PP, et al. Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is associated with poor outcome in childhood AML regardless of FLT3-ITD status: a report from the Children's Oncology Group. Br J Haematol. 2014;166:254-259.
Kumar V, Abbas A, Aster J. Neoplasia. In Kumar V, Abbas A, Aster J, eds. Robbins Basic Pathology. 9th ed. Philadelphia, PA: Saunders; 2012:161-214.
Gupta N, Seth T, Mishra P, et al. Treatment of acute myeloid leukemia in children: experience from a tertiary care hematology centre in India. Indian J Pediatr. 2011;78:1211-1215.
Zhai XW, Cheng FW, Lee V, et al. Improved survival outcome of childhood acute myeloid leukemia with intensified chemotherapy in Chinese children. Pediatr Hematol Oncol. 2011;28:269-278.
Hu S, Gao L, Wang Y, et al. Analysis of prognostic factors in chinese pediatric acute myeloid leukemia. Blood. 2016;128:5258.
Farrar JE, Schuback HL, Ries RE, et al. Genomic profiling of pediatric acute myeloid leukemia reveals a changing mutational landscape from disease diagnosis to relapse. Cancer Res. 2016;76:2197-2205.
Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100:1532-1542.
Bachas C, Schuurhuis GJ, Hollink IHIM, et al. High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine. Blood. 2010;116:2752-2758.
Bachas C, Schuurhuis GJ, Reinhardt D, et al. Clinical relevance of molecular aberrations in paediatric acute myeloid leukaemia at first relapse. Br J Haematol. 2014;166:902-910.
Bachas C, Schuurhuis GJ, Zwaan CM, et al. Gene expression profiles associated with pediatric relapsed AML. PLoS ONE. 2015;10:e0121730.
Bolouri H, Farrar JE, Triche TJ, et al. Comprehensive characterization of pediatric acute myeloid leukemia reveals novel molecular features and age-specific interactions. bioRxiv. 2017. https://doi.org/10.1101/125609
Cloos J, Goemans BF, Hess CJ, et al. Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples. Leukemia. 2006;20:1217-1220.
Liang DC, Shih LY, Fu JF, et al. K-Ras mutations and N-Ras mutations in childhood acute leukemias with or without mixed-lineage leukemia gene rearrangements. Cancer. 2006;106:950-956.
Liang DC, Shih LY, Huang CF, et al. CEBPalpha mutations in childhood acute myeloid leukemia. Leukemia. 2005;19:410-414.
Liang DC, Shih LY, Hung IJ, et al. FLT3-TKD mutation in childhood acute myeloid leukemia. Leukemia. 2003;17:883-886.
Masetti R, Castelli I, Astolfi A, et al. Genomic complexity and dynamics of clonal evolution in childhood acute myeloid leukemia studied with whole-exome sequencing. Oncotarget. 2016;7:56746-56757.
Shih LY, Liang DC, Huang CF, et al. Cooperating mutations of receptor tyrosine kinases and Ras genes in childhood core-binding factor acute myeloid leukemia and a comparative analysis on paired diagnosis and relapse samples. Leukemia. 2008;22:303-307.
Shih LY, Liang DC, Huang CF, et al. AML patients with CEBPalpha mutations mostly retain identical mutant patterns but frequently change in allelic distribution at relapse: a comparative analysis on paired diagnosis and relapse samples. Leukemia. 2006;20:604-609.
Small D, Levenstein M, Kim E, et al. STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc Natl Acad Sci USA. 1994;91:459-463.
Meshinchi S, Appelbaum FR. Structural and functional alterations of FLT3 in acute myeloid leukemia. Clin Cancer Res. 2009;15:4263-4269.
Small D. FLT3 mutations: biology and treatment. Hematology Am Soc Hematol Educ Program. 2006;2006:178-184.
Kumar V, Abbas A, Aster J. Robbins Basic Pathology. 9th ed. Philadelphia, PA: Saunders; 2012.
Genetics Home Reference. PTPN11 gene. Available from: https://ghr.nlm.nih.gov/gene/PTPN11. Accessed September 02, 2019.
Yuzawa S, Opatowsky Y, Zhang Z, Mandiyan V, Lax I, Schlessinger J. Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor. Cell. 2007;130:323-334.
Graziano AC, Cardile V, Avola R, et al. Wilms' tumor gene 1 silencing inhibits proliferation of human osteosarcoma MG-63 cell line by cell cycle arrest and apoptosis activation. Oncotarget. 2017;8:13917-13931.